A network meta-analysis of nonsmall-cell lung cancer patients with an activating EGFR mutation: Should osimertinib be the first-line treatment?: Erratum

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Erratum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709271/
https://www.ncbi.nlm.nih.gov/pubmed/31393415
http://dx.doi.org/10.1097/MD.0000000000016824
_version_ 1783446171700690944
collection PubMed
description
format Online
Article
Text
id pubmed-6709271
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-67092712019-10-01 A network meta-analysis of nonsmall-cell lung cancer patients with an activating EGFR mutation: Should osimertinib be the first-line treatment?: Erratum Medicine (Baltimore) Erratum Wolters Kluwer Health 2019-08-09 /pmc/articles/PMC6709271/ /pubmed/31393415 http://dx.doi.org/10.1097/MD.0000000000016824 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle Erratum
A network meta-analysis of nonsmall-cell lung cancer patients with an activating EGFR mutation: Should osimertinib be the first-line treatment?: Erratum
title A network meta-analysis of nonsmall-cell lung cancer patients with an activating EGFR mutation: Should osimertinib be the first-line treatment?: Erratum
title_full A network meta-analysis of nonsmall-cell lung cancer patients with an activating EGFR mutation: Should osimertinib be the first-line treatment?: Erratum
title_fullStr A network meta-analysis of nonsmall-cell lung cancer patients with an activating EGFR mutation: Should osimertinib be the first-line treatment?: Erratum
title_full_unstemmed A network meta-analysis of nonsmall-cell lung cancer patients with an activating EGFR mutation: Should osimertinib be the first-line treatment?: Erratum
title_short A network meta-analysis of nonsmall-cell lung cancer patients with an activating EGFR mutation: Should osimertinib be the first-line treatment?: Erratum
title_sort network meta-analysis of nonsmall-cell lung cancer patients with an activating egfr mutation: should osimertinib be the first-line treatment?: erratum
topic Erratum
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709271/
https://www.ncbi.nlm.nih.gov/pubmed/31393415
http://dx.doi.org/10.1097/MD.0000000000016824

Ejemplares similares